Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(R)-(+)-HA-966 is an antagonist/partial agonist at the glycine site of the NMDA receptor; able to cross the blood-brain barrier.
S-enantiomer also available.
Sold with the permission of Merck Sharp and Dohme Ltd.
M. Wt | 116.12 |
Formula | C4H8N2O2 |
Storage | Desiccate at RT |
Purity | ≥98% (HPLC) |
CAS Number | 123931-04-4 |
PubChem ID | 6603720 |
InChI Key | HCKUBNLZMKAEIN-GSVOUGTGSA-N |
Smiles | N[C@@H]1CCN(O)C1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 11.61 | 100 |
The following data is based on the product molecular weight 116.12. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 8.61 mL | 43.06 mL | 86.12 mL |
5 mM | 1.72 mL | 8.61 mL | 17.22 mL |
10 mM | 0.86 mL | 4.31 mL | 8.61 mL |
50 mM | 0.17 mL | 0.86 mL | 1.72 mL |
References are publications that support the biological activity of the product.
Kemp and Priestley (1991) Effects of (+)-HA-966 and 7-chlorokynurenic acid on the kinetics of N-MthD.-aspartate receptor agonist responses in cat cultured cortical neurons. Mol.Pharmacol. 39 666 PMID: 1674587
Pullan et al (1990) Stereoselectivity for the (R)-enantiomer of HA-966 (1-hydroxy-3-aminopyrrolidone-2) at the glycine site of the N-MthD.-aspartate receptor complex. J.Neurochem. 55 1346 PMID: 1975835
Pullan et al (1991) Agonist-like character of the (R) enantiomer of 1-hydroxy-3-amino-pyrrolid-2-one (HA-966). Eur.J.Pharmacol. 208 25 PMID: 1834473
If you know of a relevant reference for (R)-(+)-HA-966, please let us know.
Keywords: (R)-(+)-HA-966, (R)-(+)-HA-966 supplier, Partial, NMDA, agonists, antagonists, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, merck, 0281, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for (R)-(+)-HA-966 include:
Paquette et al (2008) σ ligands, but not N-MthD.-aspartate antagonists, reduce levodopa-induced dyskinesias. Elife 19 111 PMID: 18281903
Do you know of a great paper that uses (R)-(+)-HA-966 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review (R)-(+)-HA-966 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.